Access read The approval was never going to be the hard part. Vitiligo and alopecia areata have both spent decades being treated by payers as appearance rather than disease, which is why neither had a systemic option until now and why topical and cosmetic camouflage remained the default. Two first-in-class systemic approvals on one day put that classification under direct pressure, and the reimbursement conversation that follows will be more consequential than the regulatory one. Watch how HTA bodies handle it, because the evidence AbbVie built is unusually well aimed at exactly that argument. Prioritising facial repigmentation alongside total body response is not a scientific convenience, it is a recognition that the burden of vitiligo concentrates in what other people can see, and a stabilisation endpoint in actively progressing patients speaks to preventing further loss rather than reversing it. Both are the sort of endpoints designed to survive a value assessment rather than merely a regulatory one. Two other things worth logging. The inclusion of adolescents from age twelve puts a JAK inhibitor into a paediatric population for a non-life-threatening indication, which is where the class safety discussion will concentrate. And commercially, this is the same machine we described at J&J: an ageing blockbuster eroding underneath while its successor collects indications, one label at a time, until the base is wide enough to replace it.